Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.73 |
| ▸ | IDO1 | P14902 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | LDHA | P00338 | 1/20 | 0.61 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | HPGDS | O60760 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ADH5 | P11766 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.46 |
| ▸ | GP6 | Q9HCN6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22051457 | 0.82 | PBRM1 (0.69) | PBRM1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL22053134 | 0.78 | PBRM1 (0.63) | PBRM1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL3397464 | 0.76 | ALDH1A1 (0.73) | PBRM1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL8294492 | 0.76 | ALDH1A1 (0.73) | PBRM1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL8429622 | 0.76 | GAA (1.00) | PBRM1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL8294486 | 0.76 | LDHA (1.00) | PBRM1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL14844440 | 0.76 | ALDH1A1 (0.73) | PBRM1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL14262602 | 0.76 | MEN1 (0.73) | PBRM1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL2645790 | 0.76 | ALDH1A1 (0.73) | PBRM1ALDH1A1MEN1KMT2AL3MBTL1 | |
| SCHEMBL30153550 | 0.76 | MEN1 (0.80) | PBRM1ALDH1A1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180273573-A1 | INHIBITORS OF MENAQUINONE BIOSYNTHESIS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2018-09-27 | — | — | US | disclosed |
| EP-3356447-A1 | INHIBITORS OF MENAQUINONE BIOSYNTHESIS | Memorial Sloan-Kettering Cancer Center (US) | 2018-08-08 | — | — | EP | disclosed |
| WO-2017059411-A9 | INHIBITORS OF MENAQUINONE BIOSYNTHESIS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017059411-A9 | INHIBITORS OF MENAQUINONE BIOSYNTHESIS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2017-08-31 | — | — | WO | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-7879893-B2 | Zinc binding ligand; sustained release of insulin | NOVO NORDISK A/S (DK) | 2011-02-01 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | NOVO NORDISK A/S (DK) | 2009-05-14 | — | — | US | disclosed |
| US-7482456-B2 | antiasthmatic; antiinflammatory; minimal side effects; 8-(3-{2-(3-chlorophenyl)-4-[4-(methylsulfonyl)phenyl]-1,3-thiazol-5-yl}phenyl)-6-[1-methyl-1-(methylsulfonyl)ethyl]quinoline; 2-[5-(3-{6-[1-methyl-1-(methylsulfonyl)ethyl]quinolin-8-yl}phenyl)-4-pyridin-3-yl-1,3-thiazol-2-yl]propan-2-ol | MERCK FROSST CANADA | 2009-01-27 | — | — | US | disclosed |
| CN-100441185-C | 8- (3-biaryl) phenylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA INC (CA) | 2008-12-10 | — | — | CN | disclosed |
| EP-1585541-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING INSULIN AND LEGENDS OF INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-11-14 | — | — | EP | disclosed |
| EP-1429763-B1 | NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER | NOVO NORDISK AS (DK) | 2007-05-30 | — | — | EP | disclosed |
| US-20060223850-A1 | 8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA & CO. (CA) | 2006-10-05 | — | — | US | disclosed |
| CN-1812787-A | 8- (3-biaryl) phenylquinoline phosphodiesterase-4 inhibitors | MERCK FROSST CANADA INC (CA) | 2006-08-02 | — | — | CN | disclosed |
| EP-1635829-A1 | 8-(3-BIARYL)PHENYLQUINOLINE PHOSPHODIESTERASE-4-INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004096220-A1 | 8-(3-BIARYL)PHENYLQUINOLINE PHOSPHODIESTERASE-4-INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223850-A1 | 8-(3-Biaryl)phenylquinoline phosphodiesterase-4 inhibitors | PDE4A, PDE4B, PDE3B | PBRM1 3676/4885ALDH1A1 408/4885MEN1 3189/4885 |
| US-20180273573-A1 | INHIBITORS OF MENAQUINONE BIOSYNTHESIS | COASY, SDHA, VKORC1 | PBRM1 1028/4885ALDH1A1 1209/4885MEN1 79/4885 |
| US-20090123563-A1 | Pharmaceutical Preparations Comprising Insulin, Zinc Ions and Zinc-Binding Ligand | IAPP, IRS1, HBB | PBRM1 3110/4885ALDH1A1 4836/4885MEN1 912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.